Abiopharma

🔍 Cohler Matt (Director)

Company: 1stdibs.com, Inc. (DIBS)

Report Date: 2026-06-08

Detailed Transactions and Holdings:

• Acquired 40,926 shares of Common Stock (Direct)
  Date: 2026-06-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 115,544.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-08 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 3,653,916.00 | Footnotes: F2
• Sold 40,926 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: M | Exercise: 2026-06-08 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
• F2: Shares are held directly by Benchmark Capital Partners VII, L.P. ("BCP VII") for itself and as nominee for Benchmark Founders' Fund VII, L.P. ("BFF VII") and Benchmark Founders' Fund VII-B, L.P. ("BFF VII-B"). Benchmark Capital Management Co. VII, L.L.C. ("BCMC VII"), the general partner for BCP VII, BFF VII and BFF VII-B may be deemed to have sole voting and dispositive power over the securities. Matthew R. Cohler, a member of the Issuer's board of directors, Bruce W. Dunlevie, Peter H. Fenton, J. William Gurley, Kevin R. Harvey and Mitchell H. Lasky are the managing members of BCMC VII, and each of them may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims the existence of a "group" and disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
• F3: The restricted stock units have no expiration date.